Regeneron Pharma (REGN) PT Raised to $950 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq set for sharp drop as Amazon, Intel amplify AI spending worries
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $818.77 --0%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 41 | New: 7
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 41 | New: 7
Join SI Premium – FREE
Oppenheimer analyst Hartaj Singh raised the price target on Regeneron Pharma (NASDAQ: REGN) to $950.00 (from $900.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Regeneron (REGN) Tops Q3 EPS by $4.01, Beats on Revenue
- Ares Management, L.P. (ARES) PT Raised to $171 at RBC Capital
- Mondelez International (MDLZ) PT Raised to $72 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
